Pharma

Your Article Summary

See Latest Articles

Boehringer Ingelheim and DxS sign an agreement for a companion diagnostic to identify EGFR mutations in patients with lung cancer
Boehringer Ingelheim, 06/01/09

DxS, a personalised medicine company, and Boehringer Ingelheim, a global group of pharmaceutical companies, headquartered in Germany, have entered into an agreement to provide a companion diagnostic test kit for Boehringer Ingelheim’s compound BIBW 2992 (Tovok) to identify mutations of the EGFR in patients with non small cell lung cancer. Financial terms of the agreement are not disclosed.

Today in M&A/Partnerships...keeping you current

Receive free subspecialty "5-minute updates" via email

Inno Biologics and CEVEC Sign License Agreement for Human CAP Technology
b3c newswire, 12/09/09

Federal Advisory Committees to Meet
HealthDataManagement, 12/09/09

Mylan Announces Settlement Agreement Related to Antidepressant Effexor XR
Mylan, 12/09/09

 See all of M&A/Partnerships